Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

@article{Granger2003EffectsOC,
  title={Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial},
  author={Christopher B. Granger and John J. V. McMurray and Salim Yusuf and Peter H. Held and Eric L. Michelson and Bertil Olofsson and Jan {\"O}stergren and Marc A. Pfeffer and Karl Swedberg},
  journal={The Lancet},
  year={2003},
  volume={362},
  pages={772-776}
}
BACKGROUND Angiotensin-converting-enzyme (ACE) inhibitors improve outcome of patients with chronic heart failure (CHF). A substantial proportion of patients, however, experience no benefit from ACE inhibitors because of previous intolerance. We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in such patients not taking an ACE inhibitor. METHODS Between March, 1999, and March, 2001, we enrolled 2028 patients with symptomatic heart failure and left… Expand

Paper Mentions

Interventional Clinical Trial
Heart failure with preserved ejection fraction (HFpEF) is the fastest growing form of heart failure with a high morbidity and mortality rate, and is associated with severe exercise… Expand
ConditionsHeart Failure, Diastolic
InterventionOther
Interventional Clinical Trial
The investigators hypothesize that in patients with diabetes and acute myocardial infarction (MI), Ang II type-1 receptor blockade (AT1RB) attenuates left ventricle (LV) remodeling to a… Expand
ConditionsDiabetes
InterventionDrug
The role of angiotensin II receptor blockers in the management of heart failure
TLDR
Findings from large-scale clinical trials suggest that ARBs may improve outcomes across the CHF patient spectrum, including those with preserved or low ejection fractions, ACE-intolerant patients, in all cases as part of a polytherapeutic strategy. Expand
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
TLDR
Cedesartan has a moderate impact in preventing admissions for CHF among patients who have heart failure and LVEF higher than 40%. Expand
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
TLDR
Codesartan was generally well tolerated and significantly reduced cardiovascular deaths and hospital admissions for heart failure and there was no significant heterogeneity for candesartan results across the component trials. Expand
Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction
TLDR
ACPI/ARB dose is reduced and/or discontinued in nearly one-fifth of all ADHF admissions, and LOS is longer in the ACEI/ARB r/d group, which merits further study. Expand
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
TLDR
Although the drug had no significant effect on the primary outcome of this study, which included hospitalisations for heart failure, it modestly reduced the risk of the composite outcome of cardiovascular death, myocardial infarction, or stroke. Expand
Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial
TLDR
Additive use of olmesartan did not improve clinical outcomes but worsened renal function in hypertensive CHF patients treated with evidence-based medications, and particularly, the triple combination therapy with olmesartsan, ACE inhibitors and β-blockers was associated with increased adverse cardiac events. Expand
ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials.
  • D. Sica
  • Medicine
  • Congestive heart failure
  • 2004
TLDR
The findings of this study provide additional support for the effectiveness of angiotensin receptor blocker therapy in heart failure patients poorly tolerant of an ACE inhibitor; however, candesartan was not convincingly shown to improve the incidence/severity of hypotension, hyperkalemia, and glomerular filtration rate reductions that were the basis for ACE inhibitor intolerance in approximately 25% of the study population. Expand
Is the effect of angiotensin receptor blockade in patients with heart failure modified by treatment with aspirin? The answer is not so clear!
  • B. Massie
  • Medicine
  • European journal of heart failure
  • 2010
TLDR
The question of whether the effect of candesartan is modified by concomitant administration of aspirin in the large and heterogeneous population of heart failure patients enrolled in the Candeartan in Heart Failure—Assessment of Reduction in Mortality and Morbidity (CHARM) Program is examined. Expand
Review: Optimising the use of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure
  • J. McMurray
  • Medicine
  • Journal of the renin-angiotensin-aldosterone system : JRAAS
  • 2005
TLDR
Detailed safety analyses of the CHARM data have demonstrated that candesartan was well tolerated by patients receiving an angiotensin-converting enzyme (ACE) inhibitor (even at maximal doses) and beta-blocker, and by patients previously intolerant to an ACE inhibitor. Expand
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction Trials
TLDR
Candesartan significantly reduces all-cause mortality, cardiovascular death, and heart failure hospitalizations in patients with CHF and LVEF ≤40% when added to standard therapies including ACE inhibitors, β-blockers, and an aldosterone antagonist. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.
TLDR
Cedesartan was well tolerated by this population of patients with congestive heart failure and the effect of candesartan on major clinical end points, including death, remains to be determined. Expand
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
TLDR
Codesartan was generally well tolerated and significantly reduced cardiovascular deaths and hospital admissions for heart failure and there was no significant heterogeneity for candesartan results across the component trials. Expand
Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.
TLDR
The CHARM program is a program designed to investigate the clinical usefulness of the long-acting angiotensin II type 1 receptor blocker, candesartan cilexetil, in a broad spectrum of patients with symptomatic heart failure, and to evaluate the effects on the combined endpoint of cardiovascular mortality or CHF hospitalization. Expand
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
TLDR
Val-HeFT has provided the first placebo-controlled outcome data demonstrating a favorable effect of an angiotensin receptor blocker on mortality and morbidity in patients with chronic heart failure not treated with ACE inhibitors. Expand
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
TLDR
Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy, and raises concern about the potential safety of this specific combination. Expand
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients
TLDR
Although there was a trend towards greater reduction in risk of death or readmission for heart failure in patients with lower ejection fractions, benefit was apparent over the range examined. Expand
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry.
TLDR
The SPICE Registry provides a contemporary description of the demographics and management of patients with documented left ventricular systolic dysfunction and the contemporary use of ACE inhibitors appears to be higher than previously reported and the main reason for non-use is perceived intolerance. Expand
Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.
TLDR
Treatment with candesartan cilexetil demonstrated significant improvements in exercise tolerance, cardiothoracic ratio, and symptoms and signs of CHF and was well tolerated. Expand
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.
TLDR
Reductions for total mortality and the combined endpoint were similar for various subgroups examined, but patients with the lowest ejection fraction appeared to have the greatest benefit. Expand
Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure
TLDR
Total mortality and hospitalization for congestive heart failure are significantly reduced by ACE inhibitors with consistent effects in a broad range of patients. Expand
...
1
2
...